Details

Autor(en) / Beteiligte

• Papi, Alberto
• Singh, Dave
• Petruzzelli, Stefano
• Guasconi, Alessandro
• Vestbo, Jørgen

Titel

Inhaled triple therapy in chronic obstructive pulmonary disease – Authors' reply

Ist Teil von

• The Lancet (British edition), 2018-09, Vol.392 (10153), p.1113-1114

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• On the basis of previous studies,1,2 Marchand questions whether the withdrawal of inhaled corticosteroids (ICS) in a proportion of patients randomised to a combination of a long-acting β-agonist and a long-acting anticholinergic (LABA/LAMA) in the TRIBUTE study3 could be responsible for the observed difference in moderate-to-severe exacerbation rates. [...]the difference in exacerbation rate between groups in the TRIBUTE study is unlikely to be attributable to ICS withdrawal at study entry. Mathieu Molimard and colleagues wonder whether the distribution of exacerbations per patient in the two treatment groups of the study could have influenced the statistical output of the study, as reported in previous analyses.4 Here, we provide the distribution of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations in the two treatment groups in the TRIBUTE trial (table).